Drugs in Dev. Infections and Infectious Diseases
Phase I
Sweden 
Lead Product(s) : PulmoStem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the study is to evaluate the safety and tolerability of intravenous dosing of PulmoStem (amniopul-02) in patients with severe lower respiratory tract infections, including COVID-19, Influenza A, Metapneumovirus and Respiratory Sy...
Product Name : PulmoStem
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : PulmoStem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BSG005
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of laboratory and preclinical studies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : BSG005
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AmnioPul-02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI
Details : AmnioPul-02 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : AmnioPul-02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BSG005
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.
Details : BSG005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Invasive Fungal Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : BSG005
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Wharton\'S Jelly Derived Allogenic Mesenchymal Stromal Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Karolinska Trial Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wharton'S Jelly Derived Allogenic Mesenchymal Stromal Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 21, 2021
Lead Product(s) : Wharton\'S Jelly Derived Allogenic Mesenchymal Stromal Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Karolinska Trial Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP1189
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BRIEF-Synact Pharma Applies For Patent For Ap1189 Within Covid-19
Details : Company has filed a patent application to the European Patent Office covering the use of AP1189 for the treatment of COVID-19 infection, ARDS and SIRS.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : AP1189
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vicore Pharma has submitted a Letter of Intent to file a clinical trial application to the UK regulatory agency for a phase II study with its proprietary compound C21 in patients with COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
